World's Best Scientists 2026 revealed!
Gunter von Minckwitz

Gunter von Minckwitz

D-Index & Metrics

Medicine

D-Index
108
Citations
60487
World Ranking
5895
National Ranking
333

Overview

Gunter von Minckwitz is affiliated with the University of Ulm in Germany. Their research primarily revolves around oncology, with a significant focus on breast cancer treatments and related molecular studies. They have contributed extensively to the fields of medicine and biochemistry, genetics, and molecular biology.

Their work covers several subfields of study, including oncology, cancer research, pulmonary and respiratory medicine, pathology and forensic medicine, and genetics. In particular, their research interests are centered on breast cancer treatment studies, HER2/EGFR in cancer research, advanced breast cancer therapies, cancer treatment and pharmacology, breast lesions and carcinomas, cancer genomics and diagnostics, and cancer-related molecular pathways.

Gunter von Minckwitz has published in a number of prominent scientific journals, among which the most frequent venues include:

  • Cancer Research
  • Journal of Clinical Oncology
  • Annals of Oncology
  • JAMA Oncology
  • JAMA Surgery

Some of their recent publications include:

  • Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial (2021, Journal of Clinical Oncology)
  • Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer (2020, JAMA Surgery)
  • Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE (2021, Annals of Oncology)
  • PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane-Based Neoadjuvant Chemotherapy (2020, Cancer Research and Treatment)
  • Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer (2021, JAMA Oncology)

Collaboration is an important aspect of their research, having frequently worked with a range of co-authors. Notable frequent co-authors include Sibylle Loibl, Michael Untch, Norman Wolmark, Charles E. Geyer, and Carsten Denkert.

Their scientific output is characterized by exploration of molecular mechanisms underlying breast cancer and the development of therapeutic approaches based on targeted therapies and biomarkers. This is reflected in their focus on topics such as HER2/EGFR pathways and the evaluation of treatment responses in high-risk and triple-negative breast cancer cohorts.

Best Publications

  • Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

    Patricia Cortazar;Lijun Zhang;Michael Untch;Keyur Mehta

  • Adjuvant trastuzumab in HER2-positive breast cancer.

    Dennis Slamon;Wolfgang Eiermann;Nicholas Robert;Tadeusz Pienkowski

  • Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes

    Gunter von Minckwitz;Michael Untch;Jens-Uwe Blohmer;Serban D. Costa

  • Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

    Gunter Von Minckwitz;Chiun Sheng Huang;Max S. Mano;Sibylle Loibl

  • Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer

    Carsten Denkert;Sibylle Loibl;Aurelia Noske;Marc Roller

  • Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy

    Carsten Denkert;Gunter von Minckwitz;Silvia Darb-Esfahani;Bianca Lederer

  • Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

    Gunter von Minckwitz;Marion Procter;Evandro de Azambuja;Dimitrios Zardavas

  • Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers

    Carsten Denkert;Gunter von Minckwitz;Jan C. Brase;Bruno V. Sinn

  • Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial

    Gunter von Minckwitz;Andreas Schneeweiss;Sibylle Loibl;Christoph Salat

  • Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

    Bernard Asselain;William Barlow;John Bartlett;Jonas Bergh

  • Recommendations From an International Expert Panel on the Use of Neoadjuvant (Primary) Systemic Treatment of Operable Breast Cancer: An Update

    Manfred Kaufmann;Gabriel N. Hortobagyi;Aron Goldhirsch;Suzy Scholl

  • Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials

    J. Bergh;K. Pritchard;K. Albain;S. Anderson

  • Molecular alterations in triple-negative breast cancer—the road to new treatment strategies

    Carsten Denkert;Cornelia Liedtke;Andrew Tutt;Gunter von Minckwitz

  • Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial

    Sibylle Loibl;Joyce O'Shaughnessy;Michael Untch;William M Sikov

  • Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

    Miguel Martin;Frankie A Holmes;Bent Ejlertsen;Suzette Delaloge

  • Neoadjuvant Treatment With Trastuzumab in HER2-Positive Breast Cancer: Results From the GeparQuattro Study

    Michael Untch;Mahdi Rezai;Sibylle Loibl;Peter A. Fasching

  • Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: Results From the TECHNO Trial of the AGO and GBG Study Groups

    Michael Untch;Peter A. Fasching;Gottfried E. Konecny;Stephan Hasmüller

  • Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial

    Jack Cuzick;Ivana Sestak;John F Forbes;Mitch Dowsett

  • Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

    Arlene Chan;Suzette Delaloge;Frankie A Holmes;Beverly Moy

  • A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study

    S. Loibl;M. Untch;N. Burchardi;J. Huober

Frequent Co-Authors

Sibylle Loibl
Sibylle Loibl Goethe University Frankfurt
Michael Untch
Michael Untch Helios Klinikum Berlin-Buch
Carsten Denkert
Carsten Denkert Philipp University of Marburg
Christian Jackisch
Christian Jackisch Breast Cancer Research Foundation
Jens Huober
Jens Huober Kantonsspital St. Gallen
Andreas Schneeweiss
Andreas Schneeweiss German Cancer Research Center
Jens-Uwe Blohmer
Jens-Uwe Blohmer Charité - University Medicine Berlin
Christoph Thomssen
Christoph Thomssen University of Göttingen
Nadia Harbeck
Nadia Harbeck Ludwig-Maximilians-Universität München
Tanja Fehm
Tanja Fehm Heinrich Heine University Düsseldorf

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering studying Medicine in the USA, there are several related online degrees and career pathways worth exploring. For those interested in the administrative side of healthcare, medical billing and coding schools online provide the flexibility to learn vital skills remotely, often with financial aid options.

Nursing remains a popular and rewarding pathway. Many choose nursing schools that don't require teas for admission, making the process more accessible and less stressful for students seeking a streamlined entry into nursing programs.

If leadership or management in healthcare interests you, healthcare administration programs offer accelerated options that help you quickly gain the knowledge needed to advance in various healthcare organizations.

For nurses aiming to advance their careers and become family nurse practitioners, adn to fnp programs provide a direct bridge from an associate to a master's degree. These online programs support working professionals looking to broaden their clinical capabilities and impact within the healthcare sector.

Best Scientists Citing Gunter von Minckwitz

Trending Scientists